Long Term Administration of Inhaled Mannitol in Cystic Fibrosis
Long Term Administration of Inhaled Mannitol in Cystic Fibrosis- A Safety and Efficacy Study
Sponsor: Europe: KasaConsult bvba, Hoegaarden, Belgium
Listed as NCT00630812, this PHASE3 trial focuses on Cystic Fibrosis and remains completed. Sponsored by Europe: KasaConsult bvba, Hoegaarden, Belgium, it has been updated 10 times since 2008, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Feb 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Mar 2024 [monthly]
Completed PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Europe: KasaConsult bvba, Hoegaarden, Belgium
- Resolution Latin America
- Syntara
- ethica Clinical Research Inc.
For direct contact, visit the study record on ClinicalTrials.gov .